Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
Recruiting now
Conditions studied: Multiple Myeloma
In brief
The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.
Key facts
- Study ID
- NCT06659276
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- People needed
- 83
- Starts
- 2022-09-01
- Expected to finish
- 2027-10-10
- Last updated by the study team
- 2024-10-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase
- Patients who have signed the informed consent form
You may not qualify if…
- Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years
- Age < 18 years
- Women who are breastfeeding or pregnant
- Patients with metal implants or devices that constitute an absolute contraindication for MRI
- Patients with severe claustrophobia
- Patients with bone pain that prevents prolonged maintenance of the supine position
Where it is running
- Policlinico S.Orsola Malpighi — Bologna, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.